Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
PODCAST | Finance

Biotech IPOs, Avalon & FDA at SCOTUS: a BioCentury podcast

Plus: assessing FDA’s first complete response letter for lack of confirmatory trial enrollment

By Jeff Cranmer, Executive Editor
April 2, 2024 12:58 AM UTC

Upcoming catalysts could drive value creation at NASDAQ’s newest biotech,  Boundless Bio Inc. (NASDAQ:BOLD), after it stumbled in its trading debut last week. On the latest BioCentury This Week podcast, BioCentury’s editors discuss Boundless’ IPO in the context of the current market for fresh paper and profile the “sweat equity” model of Avalon BioVentures, the VC firm led by Jay Lichter.

Turning to Washington, BioCentury’s editors assess possible outcomes for the Supreme Court case on abortion drug mifepristone, and why the court’s pending decision could safeguard FDA from judicial second-guessing. The team also analyzes the agency’s first ever complete response letter for lack of confirmatory trial enrollment.

For information on opportunities to sponsor The BioCentury Show and the BioCentury This Week podcast, please email conferences@biocentury.com.

Purchase Reprint/Distribution Rights
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Boundless Bio Inc.

Regeneron Pharmaceuticals Inc.